Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 7/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.36 |
| ▸ | FAP | Q12884 | 2/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP8 | P22894 | 1/20 | 0.34 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
| ▸ | METAP2 | P50579 | 1/20 | 0.30 |
| ▸ | GLS | O94925 | 1/20 | 0.30 |
| ▸ | ARG1 | P05089 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15386492 | 0.90 | DPP4 (0.41) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL13285826 | 0.90 | DPP4 (0.41) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL16388148 | 0.86 | MMP1 (0.35) | DPP4MMP1MMP8ADAM17CTSB | |
| SCHEMBL15028132 | 0.82 | DPP4 (0.38) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL19221622 | 0.80 | MMP1 (0.39) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL17814216 | 0.79 | DPP4 (0.55) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL15028167 | 0.76 | DPP4 (0.55) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL13259713 | 0.76 | DPP4 (0.40) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL31074241 | 0.74 | DPP4 (0.41) | DPP4DPP7MMP1MMP8ADAM17 | |
| SCHEMBL418389 | 0.72 | MMP1 (0.38) | DPP4MMP1MMP8ADAM17GLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160250237-A1 | SOFT PROTEASE INHIBITORS AND PRO-SOFT FORMS THEREOF | BACH BIOSCIENCES, LLC | 2016-09-01 | — | — | US | disclosed |
| US-8563533-B2 | Soft protease inhibitors and pro-soft forms thereof | TRUSTEES OF TUFTS COLLEGE (US) | 2013-10-22 | — | — | US | disclosed |
| US-20130150292-A1 | Soft Protease Inhibitors and Pro-Soft Forms Thereof | TRUSTEES OF TUFTS COLLEGE (US) | 2013-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150292-A1 | Soft Protease Inhibitors and Pro-Soft Forms Thereof | PREP, DPP4, PEPD | DPP4 2/4885DPP8 13/4885DPP9 12/4885 |
| US-20160250237-A1 | SOFT PROTEASE INHIBITORS AND PRO-SOFT FORMS THEREOF | PREP, DPP4, PEPD | DPP4 2/4885DPP8 13/4885DPP9 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.